Influenza virus vaccine composition and methods of use

US8821890B2 · kind B2 · utility

Assignee

• Vical Incorporated · US

Inventors

• Catherine J. Luke · Frederick, US
• Adrian Vilalta · San Diego, US
• Mary Kopke Wloch · San Diego, US
• Thomas G. Evans · New York, US
• Andrew Geall · Littleton, US
• Gretchen S. Jimenez · San Diego, US

Key dates

• Filing date: Sep 30, 2011
• Grant date: Sep 2, 2014
• Expiry date: Jul 12, 2032

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C12N2760/16151
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention is directed to compositions and methods for enhancing the immune response of a human in need of protection against influenza virus (IV) infection by administering in vivo, into a tissue of the human, at least one polynucleotide comprising one or more regions of nucleic acid encoding an IV protein or a fragment, a variant, or a derivative thereof, or a protein encoded thereby. The polynucleotide is incorporated into the cells of the human in vivo, and an immunologically effective amount of an immunogenic epitope of an IV, or a fragment, variant, or derivative thereof is produced in vivo. The IV protein (in purified form or in the form of an inactivated IV vaccine) is also administered in an immunologically effective amount.